Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

Blood

Volumn 99, Issue 5, 2002, Pages 1578-1584

  Stasi, Roberto ^a,b,c   Brunetti, Maurizio ^a,b,c   Terzoli, Edmondo ^a,b,c   Amadori, Sergio ^a,b,c  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRY SKIN; ERYTHEMA; ERYTHROID CELL; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION SITE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL; TREATMENT OUTCOME;

EID: 0036493358     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1578     Document Type: Article

References (20)

1. Cytokine therapy for myelodysplastic syndrome
2. Differentiation therapy in myelodysplastic syndromes
3. Treatment of myelodysplastic syndromes with all-trans retinoic acid: Leukemia Study Group of the Ministry of Health and Welfare
4. All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study
5. All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome
6. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors
7. Effects of G-CSF, EPO, ATRA and the CD95 blocking antibody F(ab′)2 on in vitro apoptosis and proliferation in myelodysplastic bone marrow
8. Retinoids in cancer therapy
9. Pharmacokinetics of all-trans retinoic acid administered on an intermittent schedule
10. Ali-trans retinoic acid in hematological malignancies: An update
11. International scoring system for evaluating prognosis in myelodysplastic syndromes
12. Proposals for the classification of the myelodysplastic syndromes
13. Reporting results of cancer treatment
14. Report of an international working group to standardize response criteria for myelodysplastic syndromes
15. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia
16. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
17. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin
18. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
19. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
20. The role of apoptosis, proliferation, and the bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS